Financial Data and Key Metrics Changes - Q4 revenue reached $304 million, growing 24% year-over-year and 12% organically [6][20] - Full year revenue increased 17% year-over-year to $1.1 billion, with organic growth of 13% [20] - Adjusted EBITDA for Q4 was $129 million, up 29% year-over-year, with a margin of 42.5% [9][24] - Unlevered free cash flow was $80 million in Q4 and $365 million for the full year, converting 79% of adjusted EBITDA to unlevered free cash flow [25] Business Line Data and Key Metrics Changes - Subscription revenue for Q4 was $168 million, increasing 38% year-over-year and 25% sequentially, representing 55% of total revenue [23] - Volume-based revenue for Q4 was $134 million, up 11% year-over-year, with steady double-digit growth from both provider solution transactions and patient payment dollars [24] - The number of clients generating more than $100,000 of trailing twelve-month revenue increased by 85 in Q4, totaling 1,391 clients [21] Market Data and Key Metrics Changes - Waystar added 85 clients with trailing twelve-month spend above $100,000, reflecting strong demand and competitive momentum [7] - The company achieved a Net Revenue Retention rate of 112% and a Gross Revenue Retention rate of 97% [8][22] Company Strategy and Development Direction - The acquisition of Iodine Software expanded Waystar's addressable market and strengthened its competitive position [5] - The company aims to lead in AI-powered revenue cycle automation, with approximately 50% of its solutions leveraging AI [12] - Waystar's strategy focuses on delivering a unified financial and clinical platform to enhance operational efficiency and client value [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of the business model and the ability to sustain profitable growth [6] - The company anticipates revenue growth of $1.274 billion to $1.294 billion for 2026, representing 17% year-over-year growth [26] - Management expects continued healthy utilization of the healthcare system by patients throughout 2026 [26][65] Other Important Information - Waystar's platform is designed to integrate AI capabilities seamlessly, enhancing operational efficiency and client trust [39][61] - The company is focused on maintaining a leverage ratio at or below 3x and plans to continue deleveraging in line with historical rates [25] Q&A Session Summary Question: What is the appetite of customers to use LLMs versus buying from Waystar? - Management noted that most clients prefer to integrate AI capabilities into their existing systems rather than developing them independently due to a lack of engineering talent [39] Question: How do new AI agents impact revenue opportunities? - New AI capabilities will create both incremental revenue opportunities and enhance existing software modules, driving retention and elongation of client relationships [42] Question: What are the implications of increased G&A and R&D costs? - The increase is largely due to the inclusion of Iodine, and management expects to find additional opportunities for cost savings while focusing on long-term revenue growth [46][48] Question: How does Waystar's ROI compare to competitors? - Management emphasized that Waystar's ROI is compelling, supported by strong win rates and the benefits of a platform approach [81] Question: What is the outlook for AI market growth in healthcare? - Management believes the AI opportunity in healthcare is significant, with a focus on delivering secure, scalable, and accurate solutions [58][61]